Furthermore, its therapy significantly reduced the serum levels of TNF-α and IL-6, inhibited NF-kB activity, lowered the nuclear factor of activated T-cell protein production, and increased the A20 protein expression in SLE-prone NZB/W F1 mice. This evidence concerns the gene NFKB1 and systemic lupus erythematosus.